The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radiation therapy

Feng Ming Kong, Xiaoping Ao, Li Wang, Theodore S. Lawrence

Research output: Contribution to journalReview article

63 Citations (Scopus)

Abstract

Background: Radiation-induced lung toxicity (RILT) is an important dose-limiting toxicity during thoracic radiotherapy. Early prediction of radiation lung toxicity will allow physicians to determine a customized treatment regimen for each patient and deliver a radiation dose tailored to that individual's normal tissue sensitivity profile rather than to the average tolerance of the whole population. Methods: This review focuses on blood biomarkers in predicting radiation-induced lung toxicity. We searched the literature for data associated with cytokines, and we review the updates of proteomic and genetic polymorphisms in radiation lung toxicity. Results: Studies from single institutions have demonstrated the significant values of cytokines such as TGF-β1, IL-6, KL-6, surfactant proteins, and IL-1ra on predicting RILT. The majority of studies focus on the values prior to and at the end of radiation therapy. There is limited data from proteomics and specific genomic single nucleotide polymorphism studies that target individualized radiation therapy for patients with lung cancer. Conclusions: Biomarkers or models that can accurately predict radiation-induced lung damage at an early stage, before completion of chemoradiation, would allow physicians to monitor and customize remaining treatment for each patient.

Original languageEnglish (US)
Pages (from-to)140-150
Number of pages11
JournalCancer Control
Volume15
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Radiotherapy
Thorax
Biomarkers
Radiation
Lung
Proteomics
Cytokines
Interleukin 1 Receptor Antagonist Protein
Background Radiation
Physicians
Genetic Polymorphisms
Surface-Active Agents
Single Nucleotide Polymorphism
Interleukin-6
Lung Neoplasms
Therapeutics
Population
Proteins

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The use of blood biomarkers to predict radiation lung toxicity : A potential strategy to individualize thoracic radiation therapy. / Kong, Feng Ming; Ao, Xiaoping; Wang, Li; Lawrence, Theodore S.

In: Cancer Control, Vol. 15, No. 2, 04.2008, p. 140-150.

Research output: Contribution to journalReview article

Kong, Feng Ming ; Ao, Xiaoping ; Wang, Li ; Lawrence, Theodore S. / The use of blood biomarkers to predict radiation lung toxicity : A potential strategy to individualize thoracic radiation therapy. In: Cancer Control. 2008 ; Vol. 15, No. 2. pp. 140-150.
@article{cc57e1fdd6b840e5bdf9731d57ddc703,
title = "The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radiation therapy",
abstract = "Background: Radiation-induced lung toxicity (RILT) is an important dose-limiting toxicity during thoracic radiotherapy. Early prediction of radiation lung toxicity will allow physicians to determine a customized treatment regimen for each patient and deliver a radiation dose tailored to that individual's normal tissue sensitivity profile rather than to the average tolerance of the whole population. Methods: This review focuses on blood biomarkers in predicting radiation-induced lung toxicity. We searched the literature for data associated with cytokines, and we review the updates of proteomic and genetic polymorphisms in radiation lung toxicity. Results: Studies from single institutions have demonstrated the significant values of cytokines such as TGF-β1, IL-6, KL-6, surfactant proteins, and IL-1ra on predicting RILT. The majority of studies focus on the values prior to and at the end of radiation therapy. There is limited data from proteomics and specific genomic single nucleotide polymorphism studies that target individualized radiation therapy for patients with lung cancer. Conclusions: Biomarkers or models that can accurately predict radiation-induced lung damage at an early stage, before completion of chemoradiation, would allow physicians to monitor and customize remaining treatment for each patient.",
author = "Kong, {Feng Ming} and Xiaoping Ao and Li Wang and Lawrence, {Theodore S.}",
year = "2008",
month = "4",
doi = "10.1177/107327480801500206",
language = "English (US)",
volume = "15",
pages = "140--150",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "2",

}

TY - JOUR

T1 - The use of blood biomarkers to predict radiation lung toxicity

T2 - A potential strategy to individualize thoracic radiation therapy

AU - Kong, Feng Ming

AU - Ao, Xiaoping

AU - Wang, Li

AU - Lawrence, Theodore S.

PY - 2008/4

Y1 - 2008/4

N2 - Background: Radiation-induced lung toxicity (RILT) is an important dose-limiting toxicity during thoracic radiotherapy. Early prediction of radiation lung toxicity will allow physicians to determine a customized treatment regimen for each patient and deliver a radiation dose tailored to that individual's normal tissue sensitivity profile rather than to the average tolerance of the whole population. Methods: This review focuses on blood biomarkers in predicting radiation-induced lung toxicity. We searched the literature for data associated with cytokines, and we review the updates of proteomic and genetic polymorphisms in radiation lung toxicity. Results: Studies from single institutions have demonstrated the significant values of cytokines such as TGF-β1, IL-6, KL-6, surfactant proteins, and IL-1ra on predicting RILT. The majority of studies focus on the values prior to and at the end of radiation therapy. There is limited data from proteomics and specific genomic single nucleotide polymorphism studies that target individualized radiation therapy for patients with lung cancer. Conclusions: Biomarkers or models that can accurately predict radiation-induced lung damage at an early stage, before completion of chemoradiation, would allow physicians to monitor and customize remaining treatment for each patient.

AB - Background: Radiation-induced lung toxicity (RILT) is an important dose-limiting toxicity during thoracic radiotherapy. Early prediction of radiation lung toxicity will allow physicians to determine a customized treatment regimen for each patient and deliver a radiation dose tailored to that individual's normal tissue sensitivity profile rather than to the average tolerance of the whole population. Methods: This review focuses on blood biomarkers in predicting radiation-induced lung toxicity. We searched the literature for data associated with cytokines, and we review the updates of proteomic and genetic polymorphisms in radiation lung toxicity. Results: Studies from single institutions have demonstrated the significant values of cytokines such as TGF-β1, IL-6, KL-6, surfactant proteins, and IL-1ra on predicting RILT. The majority of studies focus on the values prior to and at the end of radiation therapy. There is limited data from proteomics and specific genomic single nucleotide polymorphism studies that target individualized radiation therapy for patients with lung cancer. Conclusions: Biomarkers or models that can accurately predict radiation-induced lung damage at an early stage, before completion of chemoradiation, would allow physicians to monitor and customize remaining treatment for each patient.

UR - http://www.scopus.com/inward/record.url?scp=49649100905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649100905&partnerID=8YFLogxK

U2 - 10.1177/107327480801500206

DO - 10.1177/107327480801500206

M3 - Review article

C2 - 18376381

AN - SCOPUS:49649100905

VL - 15

SP - 140

EP - 150

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 2

ER -